KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Non-Current Liabilities: 2009-2025

Historic Total Non-Current Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $21.1 billion.

  • Teva Pharmaceutical Industries' Total Non-Current Liabilities fell 2.16% to $21.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 billion, marking a year-over-year decrease of 2.16%. This contributed to the annual value of $20.8 billion for FY2024, which is 9.94% down from last year.
  • According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' Total Non-Current Liabilities is $21.1 billion, which was down 1.52% from $21.4 billion recorded in Q2 2025.
  • Teva Pharmaceutical Industries' 5-year Total Non-Current Liabilities high stood at $25.9 billion for Q1 2021, and its period low was $20.8 billion during Q4 2024.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $21.6 billion (2024), whereas its average is $22.2 billion.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first climbed by 0.44% in 2023, then declined by 12.66% in 2024.
  • Teva Pharmaceutical Industries' Total Non-Current Liabilities (Quarterly) stood at $25.4 billion in 2021, then declined by 5.71% to $23.9 billion in 2022, then fell by 3.50% to $23.1 billion in 2023, then dropped by 9.94% to $20.8 billion in 2024, then fell by 2.16% to $21.1 billion in 2025.
  • Its Total Non-Current Liabilities stands at $21.1 billion for Q3 2025, versus $21.4 billion for Q2 2025 and $21.0 billion for Q1 2025.